Member Info for PM2022

News of merger being completed can break at any time. After many months of DD and it appears funding has been done. Stella and Valirx would likely have done detailed DD as well.

The market cap is so low, MM will likely have to gap up at least 200% at this price and that even before 201 is priced in even after the gap up.

201 highly likely to be signed. Val has so much more as well which is worth much more than our market cap.

Opportunity to top up.

Tree Shakes – if you hold shares in a company and the price starts to drift downwards, you need to check two things. Firstly check the date and make sure it is not ex-dividend day – your share price will drop by the same amount as the dividend, and this is fine.

Secondly, scour the news for reasons why the sp might be dropping. If you can’t find any good reason, then the chances are that you are witnessing a “tree shake”. When a market maker is trying to fill a large institutional buy order, sometimes they may not have enough shares. They start to gradually drop the share price in order to “scare” people into thinking the company has a problem.

Weak holders will sell up, and the market maker continues to drop the price until enough weak holders have relinquished their shares. The market maker then fulfils its large order and returns the share price to where it started. Be eagle-eyed for all news relating to companies you hold shares in, and you’ll be better able to spot tree shakes and not get caught out.

That is a standard statement. As it is a LOI nothing can be guaranteed. The merger is very likely to go ahead as would have spent months doing DD and funding appears to be in place.

I don't agree 4p can happen unless 201 completely fails and even then I don't think people would sell below a certain price. I think 9p would be oversubscribed vs a chance of a gap up to 25p/30p or more

If 8p = 1.25 million = 12 months WCP if you also include revenue projections without deal = 116 approx million shares.

If 201 happens after the SP should still hit 30/40p. However, SP may increase significantly with any rumour at this point, news breaking out, suspension pending news OR GAP UP.

Risk to reward is proven to be invested. In my honest opinion.

CYPP- Feels like a 5 year old deramping.

73% of deals are at the preclinical stage. CLX= Preclinical.

Hopefully that makes sense.

Agree, I don't think it is necessary at this moment of time.

Add if you wish. I don't think we have any doubts that TRX has funding anyway.

Nothing will change the opinion of the few who will just twist the facts. We have seen that over the last 3 years.

That was the market opinion on 201 not mine and I had my reasons based on my research. Had everyone listened we would not have dropped.

Fact now is that the reversal is on the cards.

In the end only the outcome matters and at the moment it is highly likely TRX raised funds something that most were saying was impossible but that was never logical.

Porky,

Have you ever wondered that the only people you are harming are your followers Darkhero, Ratcliff and Share4?

Is that how you treat your most loyal supporters?

Porky, I have never once said this would be a phase 3 trials but phase 2b. If it was it would likely be worth over 500 million but phase 2b does have significant value so around 100/200 million valuation for the drug. I agree more data is needed but it is all about the agreements (initial payments, milestones and royalty payments) and funding for trials. More than 95% of drugs don't get funding.

The main purpose of phase 2A trials are safety and efficiency.

As far as I remember and I looked two years ago the safety record was outstanding I think the worst side effect was slightly raised blood for one patient. Efficiency 54.5% but at lower dosage therefore a huge advantage when that is increased. Note this was also for patients at late stage prostate cancer where other treatments had failed. Therefore valuable. The fact Professor Adam purchased more on the back of those results and experts have taken the drug supports what I say over all the unqualified people trying to argue otherwise.

You will not get a large pharma take this without larger data but typical deals will be worth a few hundred million or more with huge upfront payments we got less but relative to our market cap it stil multi bags by many times just on 201 alone. I think the americans will love 201 and will buy into Valirx and we will hit new highs in the coming months.

201 is priced at zero so whether you think it is worth 20,30,50 million to Val it does not cost zero to take it this far with very promising results and the deal is also not worth zero with initial and significant milestone and royalty payments attached.

Your argument is only highlighting how valuable this is relative to our current market cap of 10 million which does not even put a value on most of our other assets. Remember everything is all relative.

I think we will re-rate to a 30/40 million market cap before Christmas provided the merger goes ahead.

Anyway give it a rest now.

Share4,

Are you an expert like Adam working in the industry in a senior position?

Are you paying for the trials?

Are you paying VAL?

NO. I'll shut up then. I have answered your question.

Did RedX do a 17 million placing at market price recently? Not quite sure but at 10 million market cap that only really factors in the listing price plus maybe 20/30% of CLX. 201 is not priced in, 201 deal is not priced in, 301 not priced in, 401 not priced in, lab plus Imogen plus collaborations not priced. In my view the chances of the deal completing are probably 90% before year end therefore triggering release of payments due to us and likely a significant gap up. Therefore no placing or a placing before a deal and a much higher price. Nothing is risk free but I like my chances.

Stock4, Your point is positive not a negative despite your best attempt. The trials were done at lower dosages so the actual results should be better than 55%. I believe this is part of the reason why Professor Adam topped on results day and this is the reason why they have backers also due to the compound being very safe. Obviously if those results were apparent in larger phase 2 trials then perhaps you would value the drug at 500 million plus in the US.

I'll post the link again to indicate how much a cancer drug could be worth at various stages.

https://www.nature.com/articles/d43747-023-00002-6

Our market cap is only 10 million and we have many other valuable compounds and a valuable lab with assets and collaborations. Initial payments plus 65 millions plus 35 odd million odd for additional indications with funding for trails. Add in potential royalty payments. Only some of that gets factored in at this stage. Still the market cap would be significantly higher.

As everyone knows Porky has been here three years. It has been widely claimed he lives a few doors away from our CEO and it is all personal. He makes up figures, statements and bends the truth. He lost serious money on 4D and perhaps lost it all.

The consolidations were due to clinical trials which are expensive and were done by the old BOD with a completely different strategy therefore your points are misleading. With the new management they have de-risked so only deal with preclinical compounds and get early deals which are in progress.

If the deal goes ahead Val gets about 1.85 million with further milestones including about 65 million plus royalties if it gets to market. Phase 2 compounds with a deal are worth a lot of money. Cash burn is just under 2 million but within that they will be generating revenue in the coming year. It is not just a lab business but a lab business that works on progressing preclinical compounds which we all know cost millions to do.

Anyway DYOR. The deal and merger is highly likely to go ahead therefore triggering release of payments due to us.

Phimx,

The strategy has changed since they came in. They have hired some of the best staff in the industry. If you look at the experience of Cathy Tralau Stewart, Zai Ahmad (pre clinical project manager) then you will know they have the foundations in place. They now have a lab, acquired Imogen in liquidation for £160k which was generating revenue of millions but went bust due to the number of staff they hired and high cash burn, they have brang in numerous promising compounds one is at pre-clinical stage and is very novel the other is at evaluation stage and two have failed. More will come soon. This compound CLX001 can get a deal that will likely be more than 10 times more valuable than the 201 deal even at pre clinical stage. As it progresses it will become more valuable.

https://www.valirx.com/cytolytix-limited

Worth watching the video above. The strategy is a low risk strategy because we don't do clinical trials anymore. If you do research then do it on the value of preclinical deals, you are probably looking at an average value of about 200 million plus. SAR went to a market cap of about 250 million pounds based on one preclinical compound which was not even that good.

https://www.nature.com/articles/d43747-023-00002-6

It takes time to implement a strategy but we are now at a stage where we will see value coming through. The company was not well managed in the past with the old management team.

The previous trial was not done so well with low patient numbers and using lower dosages. Excellent results of 54.5% but as it was done at lower dosages the expectation is that the actual results of the next trials will be far better.

Note when these results were out for the trials, Adam added to his holdings. He once stated in his opinion he felt 201 would have a much higher success rate due to lower dosages used and as these would increase the success rate should increase. We know the peptide is safe. I think based on that he added.

In regards to value, TRX are initially paying Val about 2 million pounds plus 65 million odd if the trials are successful plus royalty payments which for cancer drugs are very large. The fact TRX are risking 20 million odd to do these trials give the drug significant value. You would have to compare against other companies running phase 2 cancer trials to know the rough value of the drug at this stage. I would say about 200/300 million for a phase 2 drug with trials funded and running. Only some of that would be factored into the market cap at this stage so 30/40 million given potential payments as well.

Your comment on what drug Val has taken all the way is irrelevant. This current BOD and strategy has only existed for three years. The strategy does not involve doing trials anymore but to bring in new compounds and get a deal at the pre-clinical stage. So far we have had CLX which appears to be a blockbuster compound.

Regardless of opinion at 10 million market with 301,401, CLX, lab with assets and 201 deal your looking at significant upside.

· The headline results released in the Company announcement on 28 September 2020 highlighted the response rate of 54.5%, where response was confirmed by a lack of disease progression by PCWG2 (Prostate Cancer Working Group 2) criteria. The dataset now received provides the detailed breakdown of this by providing both the PSA modulation afforded by the treatment, and the tumour response.

· The PSA data, a recognised surrogate of disease progression, shows two patients seeing a decrease in PSA during their treatment period, one of which maintained the decrease throughout the trial. An analysis of the doubling time of patients shows a statistically significant (p

· The tumour response data demonstrates that patients did not have an increase in metastatic lesions during the treatment period, and that metastatic lesions already present did not grow at all in two out of three patients, suggesting a positive influence of VAL201 on the disease.

Safety and Tolerability

The further breakdown of the safety data confirms the well tolerated nature of the drug.

Additionally, the initial pharmacokinetic analysis supports the safety profile in confirming the drug is processed and cleared from the body in the manner expected.

That is very different to saying TRX will not raise a penny for the last two years. Your story changes as news comes when your predictions are proven wrong. You know they have raised money and the merger will get done which will almost immediately get the funds released.

Porky, you made similar statements for resolution 4, July placing and a list of other events but despite being wrong so many times you just move onto the next thing.

We will find out soon enough but if you truly believed it then you would sit back and relax rather than posting day and night. Clearly you want us to sell or alternatively maybe you care about every individual on LSE.

Anyway enjoy your weekend for a change but no doubt you will post at 4am again.

Put your money where your mouth is. Short the stock and show us.

Will you agree to never post if the merger goes ahead and TRX gets funding. No ifs or buts?

The answer is no because you know the deal will get done and Val will get funding and the SP will fly.

I don't see the relevance. The purpose of the next trial phase 2 trial is to gather more data.

To get to this stage and if funding is secured for trials with a pathway to go all the way with milestones and royalty payments agreed then who cares. Other phase 2 oncology trial drugs are worth 100/200 million plus.

I have seen the agreement in the public domain.

Also go based on the article stating that EUDA believes TRX has strong access to funds.

The purpose of the merger I believe is to provide a pathway for both companies later on after phase 2 trials are complete. They would have the funding for the trials but you are free to think what you want.

Just to remind everyone to remember Stella knows about Mergers and Acquisitions and if in doubt they would not be going the route they have with the deal expected first. TRX and EUDA would have put everything in place for it to happen within the timeframe. This is why they have already announced an extension of if I remember correctly 14/15 days only if required which will still be fine.It would be foolish of them to ask for even more. I think it will be a quick process and it will be done within the original 30 days. Lots of work would have been done regarding the merger and funds have been raised.

Porky is here to create doubts. He has something personal against the company and is not afraid to constantly lie. I think we all know now TRX has raised funds so as soon as it is signed we are good.

News breaks then anything is possible with 201 not priced in a large gap up or suspension pending announcement and people will be caught out. I don't want to be out of this stock this weekend that is for sure.

Agreed but how he thinks might be different. Why would anyone post almost every day and night on a stock for about three years with two placings and 5p gone. Would you post at 11pm and 4am almost everyday on a stock you are not invested in?

Then the same person who was actively ramping up numerous stocks has not done so in any other stock that I can see since 4D closed.

I think today proved to everyone he was not a potential buyer something I have always said. If you had intentions to buy you would not try and jeopardise the deal by posting on the EUDA site to try and stop the merger you would actually want it done regardless of your buy in price. He lost his money so for whatever reason blames us.

Val was cash rich when CLX was signed from Kings and after placing at 10p but he never invested when it took a heavy drop. All the signs support what I say. I knew then no chance he would buy.